| Mechanisms of action of valproate: a commentatory CU Johannessen Neurochemistry international 37 (2-3), 103-110, 2000 | 496 | 2000 |
| Valproate: past, present, and future CU Johannessen, SI Johannessen CNS drug reviews 9 (2), 199-216, 2003 | 476 | 2003 |
| Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy CJ Landmark CNS drugs 22, 27-47, 2008 | 467 | 2008 |
| Antiepileptic drug interactions-principles and clinical implications S I. Johannessen, C Johannessen Landmark Current neuropharmacology 8 (3), 254-267, 2010 | 432 | 2010 |
| Drug interactions involving the new second-and third-generation antiepileptic drugs C Johannessen Landmark, PN Patsalos Expert review of neurotherapeutics 10 (1), 119-140, 2010 | 392 | 2010 |
| Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications T Tomson, CJ Landmark, D Battino Epilepsia 54 (3), 405-414, 2013 | 226 | 2013 |
| Targets for antiepileptic drugs in the synapse CJ Landmark Medical science monitor 13 (1), RA1-RA7, 2006 | 217 | 2006 |
| Epilepsy and cannabidiol: a guide to treatment A Arzimanoglou, U Brandl, JH Cross, A Gil-Nagel, L Lagae, CJ Landmark, ... Epileptic Disorders, 1-14, 2020 | 154 | 2020 |
| Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population CJ Landmark, H Fossmark, PG Larsson, E Rytter, SI Johannessen Epilepsy research 95 (1-2), 51-59, 2011 | 138 | 2011 |
| Antiepileptic drugs in epilepsy and other disorders—a population-based study of prescriptions CJ Landmark, PG Larsson, E Rytter, SI Johannessen Epilepsy research 87 (1), 31-39, 2009 | 136 | 2009 |
| Host factors affecting antiepileptic drug delivery—pharmacokinetic variability CJ Landmark, SI Johannessen, T Tomson Advanced drug delivery reviews 64 (10), 896-910, 2012 | 131 | 2012 |
| Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects C Johannessen Landmark, SI Johannessen, PN Patsalos Expert opinion on drug metabolism & toxicology 16 (3), 227-238, 2020 | 127 | 2020 |
| Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines A Reimers, JA Berg, ML Burns, E Brodtkorb, SI Johannessen, ... Drug design, development and therapy, 271-280, 2018 | 120 | 2018 |
| Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication CJ Landmark, A Baftiu, I Tysse, B Valsø, PG Larsson, E Rytter, ... Therapeutic drug monitoring 34 (4), 440-445, 2012 | 105 | 2012 |
| Psychiatric comorbidity in patients with epilepsy: a population-based study M Karouni, S Arulthas, PG Larsson, E Rytter, SI Johannessen, ... European journal of clinical pharmacology 66, 1151-1160, 2010 | 104 | 2010 |
| Value of therapeutic drug monitoring in epilepsy SI Johannessen, CJ Landmark Expert review of neurotherapeutics 8 (6), 929-939, 2008 | 101 | 2008 |
| Quantification of the GABA shunt and the importance of the GABA shunt versus the 2‐oxoglutarate dehydrogenase pathway in GABAergic neurons B Hassel, CU Johannessen, U Sonnewald, F Fonnum Journal of neurochemistry 71 (4), 1511-1518, 1998 | 95 | 1998 |
| Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring CJ Landmark, SI Johannessen, T Tomson Epileptic Disorders 18 (4), 367-383, 2016 | 91 | 2016 |
| Proconvulsant effects of antidepressants—What is the current evidence? CJ Landmark, O Henning, SI Johannessen Epilepsy & Behavior 61, 287-291, 2016 | 80 | 2016 |
| Pharmacological management of epilepsy: recent advances and future prospects CJ Landmark, SI Johannessen Drugs 68, 1925-1939, 2008 | 78 | 2008 |
Svein Ivar JohannessenSeniorforsker, Oslo universitetssykehusVerifisert e-postadresse på online.no
